Network News
For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place. More information in German below: Zusammen […]
read more
CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice
Finnish animal welfare legislation (Government Decree 1165/2023) effective as of January 1, 2024, requires establishments to apply “appropriate pain relief” in association with ear notching identification method of laboratory rodents(1). However, there is a lack of scientific evidence whether the benefits of applying analgesia outweigh the additional stress related to handling and drug administration. Our […]
read more
PEPperPRINT Secures State Funding for Development of GlycoPlex Glycopeptide Array Platform
Heidelberg, 15th of May 2026 – PEPperPRINT GmbH has successfully secured additional research and development funding from the innovation funding program “Invest BW” of the German state of Baden-Württemberg for the development of its new GlycoPlex platform, a high-throughput technology for disease-relevant glycopeptide analyses. The funded project, titled “GlycoPlex – High-Throughput Platform for Disease-Relevant Glycopeptide Analyses”, […]
read more
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Paris, June 8, 2026. The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications for Sarclisa intravenous (IV) formulation. Sarclisa is […]
read more
Tracing environmental change through river microbiomes in Luxembourg
New TREC pilot project explores how microbial life along rivers reflects environmental change and supports ecosystem health The European Molecular Biology Laboratory (EMBL) and regional partners, including the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, have launched a pilot project in the Luxembourg area to investigate how microbial life within river […]
read more
Excellent doctoral training enters its second phase: Heidelberg University’s medical faculties are continuing a successful Research Training Group in the field of immunology
Joint press release from the medical faculties of Heidelberg and Mannheim The DFG is providing funding of around €5.8 million to support the continuation of Research Training Group 2727, ‘Checkpoints of Innate Immunity in Cancer and Tissue Damage (InCheck)’, led by the Faculty of Medicine in Mannheim. More information in German below: Wie funktionieren die […]
read more
Hummingbird Diagnostics to Present New Findings Linking Ribosome Quality Control Pathway to Liquid Biopsy Biomarkers for Lung Cancer at EACR
Data highlight a mechanistic link between ribosomal stress pathways and biomarker generation, with potential implications for patient stratification and treatment response HEIDELBERG, Germany, June 2, 2026 – Hummingbird Diagnostics GmbH, a molecular diagnostics company focused on blood-based tests for early disease detection and precision medicine, today announced that it will present new findings supporting the […]
read more
Why pain persists long after injuries have healed
Prof. Dr. Rohini Kuner of the Heidelberg Faculty of Medicine at Heidelberg University awarded the 2026 Jung Prize for Medicine Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the […]
read more
Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)
Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now […]
read more
